ProShare Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-14,334
| Closed | -$1.39M | – | 1821 |
|
|
2019
Q3 | $1.39M | Sell |
14,334
-931
| -6% | -$93.2K | 0.01% | 669 |
|
|
2019
Q2 | $1.56M | Sell |
15,265
-1,330
| -8% | -$144K | 0.01% | 642 |
|
|
2019
Q1 | $1.89M | Buy |
16,595
+488
| +3% | +$35.9K | 0.01% | 612 |
|
|
2018
Q4 | $630K | Sell |
16,107
-3,063
| -16% | -$133K | ﹤0.01% | 868 |
|
|
2018
Q3 | $1.05M | Sell |
19,170
-685
| -3% | -$46.8K | 0.01% | 805 |
|
|
2018
Q2 | $1.64M | Sell |
19,855
-886
| -4% | -$68.4K | 0.01% | 663 |
|
|
2018
Q1 | $1.38M | Sell |
20,741
-3,297
| -14% | -$190K | 0.01% | 713 |
|
|
2017
Q4 | $1.24M | Buy |
24,038
+1,636
| +7% | +$118K | 0.01% | 758 |
|
|
2017
Q3 | $2M | Buy |
22,402
+4,370
| +24% | +$332K | 0.02% | 558 |
|
|
2017
Q2 | $1.08M | Sell |
18,032
-739
| -4% | -$41.3K | 0.01% | 715 |
|
|
2017
Q1 | $1M | Sell |
18,771
-4,630
| -20% | -$275K | 0.01% | 745 |
|
|
2016
Q4 | $1.17M | Buy |
23,401
+1,790
| +8% | +$95.9K | 0.01% | 711 |
|
|
2016
Q3 | $1.3M | Sell |
21,611
-882
| -4% | -$50.8K | 0.02% | 618 |
|
|
2016
Q2 | $1.15M | Buy |
22,493
+1,372
| +6% | +$58.6K | 0.01% | 676 |
|
|
2016
Q1 | $623K | Buy |
21,121
+75
| +0.4% | +$2.37K | 0.01% | 904 |
|
|
2015
Q4 | $954K | Buy |
+21,046
| New | +$1.1M | 0.01% | 754 |
|
ProShare Advisors's ONCE Position: Q4 2019 in Review
ProShare Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 14,334 shares — an estimated $1.39M sold.
ProShare Advisors first reported a position in ONCE in Q4 2015 and held it in 16 quarters. The position peaked at $2M in Q3 2017. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- ProShare Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- ProShare Advisors sold 14,334 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1.39M.
- ProShare Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2015 and held it in 16 quarters.
- ProShare Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $2M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on ProShare Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.